Sugi Predict

Sugi Predict / Compounds / SCHEMBL2047698

SCHEMBL2047698

SCHEMBL2047698

Cc1[nH]c(C=C2C(=O)Nc3ccc(S(=O)(=O)N4CCc5ccccc54)cc32)c(C)c1C(=O)N1CCN(C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 5/20 1.00
▸ KDR P35968 8/20 0.63
▸ FGFR1 P11362 7/20 0.63
▸ PTK2B Q14289 3/20 0.63
▸ MEN1 O00255 2/20 0.63
▸ CDK2 P24941 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ TDP1 Q9NUW8 2/20 0.63
▸ CCNE1 P24864 1/20 0.63
▸ RECQL P46063 1/20 0.63
▸ AURKB Q96GD4 6/20 0.56
▸ AURKA O14965 4/20 0.56
▸ FLT1 P17948 2/20 0.53
▸ PDGFRB P09619 6/20 0.49
▸ EGFR P00533 2/20 0.46
▸ SRC P12931 3/20 0.46
▸ ALK Q9UM73 3/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ ABL1 P00519 2/20 0.46
▸ LCK P06239 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29392746 1.00 MET (1.00) METKDRFGFR1PTK2BMEN1
SCHEMBL29395174 1.00 MET (1.00) METKDRFGFR1PTK2BMEN1
SCHEMBL2047697 1.00 MET (1.00) METKDRFGFR1PTK2BMEN1
SCHEMBL5406536 0.96 MET (0.92) METKDRFGFR1PTK2BMEN1
SCHEMBL5406511 0.93 MET (0.88) METKDRFGFR1PTK2BMEN1
SCHEMBL5406612 0.91 MET (0.83) METKDRFGFR1PTK2BMEN1
SCHEMBL5406649 0.91 MET (0.83) METKDRFGFR1PTK2BMEN1
SCHEMBL5414499 0.91 MET (0.83) METKDRFGFR1PTK2BMEN1
SCHEMBL5405465 0.90 MET (0.82) METKDRFGFR1PTK2BMEN1
SCHEMBL5413334 0.90 MET (0.82) METKDRFGFR1PTK2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140348819-A1 Methods of Treating Cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2014-11-27 — — US claimed
US-8729043-B2 Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products METHERESIS TRANSLATIONAL RESEARCH S.A. (CH) 2014-05-20 — — US claimed
WO-2012178038-A1 METHODS OF TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2012-12-27 — — WO claimed
US-20120134996-A1 Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products METHERESIS TRANSLATIONAL RESEARCH SA, (CH) 2012-05-31 — — US claimed
EP-1981981-B1 ANTI-MET MONOCLONAL ANTIBODY, FRAGMENTS AND VECTORS THEREOF, FOR THE TREATMENT OF TUMORS AND CORRESPONDING PRODUCTS METHERESIS TRANSLATIONAL RES SA (CH) 2011-06-29 — — EP claimed
US-20090285807-A1 Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products Pierre Fabre Médicament (FR) 2009-11-19 — — US claimed
EP-4730355-A1 TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER Lumitype Medical (Huzhou) Co., Ltd. (CN) 2026-04-22 — — EP disclosed
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 — — US disclosed
EP-4541381-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2026-02-04 — — EP disclosed
EP-4545100-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2025-12-10 — — EP disclosed
EP-4541380-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2025-12-10 — — EP disclosed
EP-4545101-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2025-12-10 — — EP disclosed
US-12491272-B2 Stable, concentrated radionuclide complex solutions ADVANCED ACCELERATOR APPLICATIONS SA (FR) 2025-12-09 — — US disclosed
US-20140301946-A1 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2014-10-09 — — US disclosed
WO-2014160160-A2 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2014-10-02 — — WO disclosed
WO-2014150937-A1 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-20140271688-A1 ANTIBODY DRUG CONJUGATES IRM LLC (BM) 2014-09-18 — — US disclosed
US-8388958-B2 Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products METHERESIS TRANSLATIONAL RESEARCH SA (CH) 2013-03-05 — — US disclosed
WO-2012178038-A1 METHODS OF TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2012-12-27 — — WO disclosed
US-20090285807-A1 Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products Pierre Fabre Médicament (FR) 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 MET 1078/4885KDR 3515/4885FGFR1 2064/4885
US-20140301946-A1 ANTIBODY DRUG CONJUGATES FGFR4, FGFR2, FGFR3 MET 13/4885KDR 41/4885FGFR1 4/4885
US-12491272-B2 Stable, concentrated radionuclide complex solutions EPOR, PAICS, XPO5 MET 2278/4885KDR 4219/4885FGFR1 2593/4885
US-20140271688-A1 ANTIBODY DRUG CONJUGATES EPCAM, CD44, ABL1 MET 93/4885KDR 799/4885FGFR1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.